SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong quarterly results and raised outlook have been met with a sharp selloff, with traders citing higher capital spending, negative cash flow and a demanding valuation despite growth prospects tied to data-center power demand. The community is divided between dip buyers who see the pullback as an opportunity and skeptics who question whether growth can translate into cash generation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs continued slide to new lows is driving a largely bearish discussion, with traders linking the weakness to Trump-related political risk, the Iran conflict and rising oil prices. Many also question the companys standalone value and cite dilution, while a smaller group points to a possible technical rebound.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Leaked Phase 3 results for Moderna and Mercks personalized melanoma vaccine prompted a sharp selloff despite showing reduced recurrence risk versus Keytruda alone. Traders are divided over whether the data support the cancer-vaccine opportunity or fell short of expectations after a steep run-up, with questions about commercial scalability and a volatile rebound keeping attention on the shares.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo shares are under pressure as MaxLinear targets a share of the active electrical cable market Credo currently dominates, raising concerns about future competition. Traders are split between viewing the selloff as a buying opportunity and expecting further declines, with some also citing broader AI weakness and insider selling.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSMs steep selloff has focused attention on uncertainty around Auvelitys commercial ramp, particularly whether prescription growth is lagging expectations after its launch for Alzheimers-related agitation. Traders debate whether sluggish reported scripts signal slower adoption and sales-execution concerns or undercounting from samples and long-term-care channels, while seeking clarity from management ahead of Q3 results.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

FIGR is drawing attention amid a steep selloff and repeated tests of support, with bearish traders warning of further losses and citing insider-share overhang, dilution concerns, and distrust of management; bankruptcy claims remain speculation. Bulls counter that the companys growth and blockchain-based lending and tokenization platform support the long-term case, leaving the discussion sharply divided.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating U.S.-Iran tensions and threats to shipping and energy infrastructure could disrupt Middle East supply; traders also cite falling inventories. Bulls see room for further gains, while bears argue the move is headline-driven and vulnerable to a sharp reversal if tensions ease.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs continued slide is drawing attention amid traders concerns that its large distribution may be cut, alongside doubts about Icahn Enterprises declining asset value, debt and management. Some holders argue its stake in CVR Energy and other assets is undervalued and cite short-squeeze potential, but these remain bullish speculation against a broadly worried sentiment.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a volatile tech-led selloff and rebound, with traders debating whether concerns about AI spending and financing, alongside rising oil and Iran-related uncertainty, will keep pressure on technology stocks. The community is split between buying the dip and expecting another leg lower.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A sharp gold selloff has traders debating whether higher-rate and dollar pressures, along with broader market liquidation, are driving further weakness or creating a buying opportunity near support. Many question golds safe-haven behavior as it falls alongside risk assets, while others expect a rebound and are adding on dips.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CYDY between wphyaxsand cytomight&#39;s post today on Dr Jays report to shareholders and along with wphyaxs info on phase 2 approvals here&#39;s my take. I now STRONGLY believe that the FDA/cydy team are working on a EUA/fast track approval for our triple neg breast cancer. It is obvious it&#39;s not a matter of if but when from Dr Jay&#39;s comments! No way he says what he does to investors without knowing the FDA and cydy are in that process. They have provided the data withheld from Amerex and we have gathered the current status of the living cancer free trial patients. This is so monumental!! The reason we are not getting our due/props/share rise is we are cydy. Tainted by the untrue and misleading wrath of the old FDA staff, Amerex sabotage, Fartstain hit pieces, prior management and BP support to shorts. Now we have proof! We have data! We are safe! WE SAVE LIVES 4 Times longer than SOC and CANCER FREE!! Think of that!!! Diagnosis stage 4 death certain to 4 yrs alive cancer free!

CJ Sigler

J Valro

Todd Langevin

Brian

On The Way Out

LIVIMMUNE Bound

bellaruse

Gordon Skorstad

Tuna T

MFSalvatore

Carbide Enthusiast

Rick

T Lindsay

150K_SHARES

LAWRENCE BROWN

Yobyof

Go CYDY

Jerry

Richard Jarvis

Phil

vivamiga

Anyon

Huan Pham

StockTwits For Android 

CytoDyn Inc

 between wphyaxsand cytomight's post today on Dr Jays report to shareholders and along with wphyaxs info on phase 2 approvals here's my take. I now STRONGLY believe that the FDA/cydy team are working on a EUA/fast track approval for our triple neg breast cancer. It is obvious it's not a matter of if but when from Dr Jay's comments! No way he says what he does to investors without knowing the FDA and cydy are in that process. They have provided the data withheld from Amerex and we have gathered the current status of the living cancer free trial patients. This is so monumental!! The reason we are not getting our due/props/share rise is we are cydy. Tainted by the untrue and misleading wrath of the old FDA staff, Amerex sabotage, Fartstain hit pieces, prior management and BP support to shorts. Now we have proof! We have data! We are safe! WE SAVE LIVES 4 Times longer than SOC and CANCER FREE!! Think of that!!! Diagnosis stage 4 death certain to 4 yrs alive cancer free!

Pitt

@CydyPitt We already have Fast Track status for msTNBC, and there cannot be an EUA because there is no Emergency declared for msTNBC.   And we already applied for Breakthrough Designation for msTNBC, and were turned down.  An application for approval would require a larger sample size.  What we might be doing is preparing to announce a large Phase III study backed by another company.

StockTwits Web

 We already have Fast Track status for msTNBC, and there cannot be an EUA because there is no Emergency declared for msTNBC.   And we already applied for Breakthrough Designation for msTNBC, and were turned down.  An application for approval would require a larger sample size.  What we might be doing is preparing to announce a large Phase III study backed by another company.

Kenneth Glantz

@CydyPitt thanks PITT! Fantastic work, when can we expect this approval by? End of 2025?

StockTwits for iOS

 thanks PITT! Fantastic work, when can we expect this approval by? End of 2025?

CPKC

@KageGlantz thanks for the info. I was not aware if the application was submitted  or turned down. I&#39;m thinking the FDA is working with cydy now. What about possibly a resubmitted bla for HIV. Those results were from a much larger trial size?

 thanks for the info. I was not aware if the application was submitted  or turned down. I'm thinking the FDA is working with cydy now. What about possibly a resubmitted bla for HIV. Those results were from a much larger trial size?

@CydyPitt I hope so, I have a friend who needs it!

 I hope so, I have a friend who needs it!

@CydyPitt @KageGlantz Pitt, don’t trust that account.